Wockhardt WCK 5222 granted accelerated assessment by EMA
Written By : Ruchika Sharma
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2025-12-31 07:00 GMT | Update On 2025-12-31 07:00 GMT
Advertisement
Mumbai: Wockhardt has announced that it has been informed by the European Medicines Agency (EMA) that WCK 5222, a combination of Zidebactam 1g plus Cefepime 2g, is eligible for Accelerated Assessment, following a pre-submission meeting with the EMA review team.
The Accelerated Assessment designation reflects EMA’s view that WCK 5222 has the potential to address an unmet medical need by providing an effective therapeutic option for the treatment of serious and life-threatening infections, particularly those caused by multi-drug-resistant (MDR) and extremely drugresistant (XDR) Gram negative pathogens.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.